Technology | January 06, 2015

FDA Approves Bayer's Gadavist for Pediatric Patients Under Two

MRI contrast agent becomes the first approved for youngest pediatric patients

Bayer Healthcare, Gadavist, FDA, approval, pediatric patients, contrast media

Image courtesy of Bayer Healthcare

January 6, 2015 — Bayer HealthCare announced that the U.S. Food and Drug Administration (FDA) has approved Gadavist (gadobutrol) injection for use with magnetic resonance imaging (MRI) in pediatric patients less than 2 years of age, including term neonates, to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system. Gadavist was previously approved for this use in patient populations over the age of 2. The FDA’s priority review was based on a study showing that the pharmacokinetic (PK) and safety profiles in pediatric patients less than 2 years of age were similar to that of older children and adults at standard dose (0.1 mmol/kg).

 “Until this study, there were limited data regarding the use of gadolinium-based contrast agents in pediatric patients younger than 2 years of age, and there has been a significant need to better understand how they work in our youngest patients,” said Ravi Bhargava, M.D., study investigator and pediatric radiologist, University of Alberta, Edmonton, Canada. “Ultimately, it’s important for us to have safe and effective tools to help us accurately detect abnormalities and visualize areas of the central nervous system in children of all ages.”

The study enrolled 47 pediatric patients with ages spanning from term neonates to 23 months with normal renal function from nine centers across the United States, Canada and Europe. Forty-four pediatric patients were evaluated for safety and efficacy and 43 were eligible for a PK profile evaluation, including nine term neonates less than 2 months of age.  Safety was a secondary endpoint and the study also included a qualitative assessment of efficacy.

The data showed that the Gadavist PK profile in pediatric patients under 2 was similar to the PK profile in older pediatric patients and adults. Investigators also observed a similar safety profile for Gadavist in this pediatric population.

The study found that the Gadavist adverse event (AE) profile was consistent with what has been seen in older populations. In one patient, vomiting was reported as a mild adverse drug reaction (ADR) to Gadavist. The most common non-serious AEs unrelated to Gadavist were cough, nasopharyngitis, rhinitis, pyrexia and vomiting. Serious AEs were unrelated to Gadavist and were reported in three out of 44 patients.

Gadavist is the U.S. brand name of the aqueous 1.0M solution of gadobutrol, a gadolinium (Gd)-based extracellular contrast agent for MRI with a macrocyclic structure.

Gadavist (gadobutrol) injection was first approved in the U.S. in March 2011 for intravenous use in diagnostic MRI in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system. Gadavist was further approved in June 2014 in the U.S. for MRI of the breast to assess the presence and extent of malignant breast disease.

For more information: www.healthcare.bayer.com

Related Content

An illustration based on simulations by Rice University engineers shows a gadolinium ion (blue) in water (red and white), with inner-sphere water -- the water most affected by the gadolinium -- highlighted. The researchers’ models of gadolinium in water show there’s room for improvement in compounds used as contrast agents in clinical magnetic resonance imaging.

An illustration based on simulations by Rice University engineers shows a gadolinium ion (blue) in water (red and white), with inner-sphere water -- the water most affected by the gadolinium -- highlighted. The researchers’ models of gadolinium in water show there’s room for improvement in compounds used as contrast agents in clinical magnetic resonance imaging. Illustration by Arjun Valiya Parambathu

News | Magnetic Resonance Imaging (MRI) | September 20, 2021
September 20, 2021 — ...
Avoiding contrast dyes for imaging tests not necessary if concerned about iodine allergy, peer-reviewed study concludes #MRI

Getty Images

News | Contrast Media Injectors | September 16, 2021
September 16, 2021 — FDB (First Databank), a leading provider of drug and medical device knowledge that helps healthc
Revised guidelines for lung cancer screening eligibility are perpetuating disparities for racial/ethnic minorities, according to a new study in Radiology.

Getty Images

News | Lung Imaging | September 15, 2021
September 15, 2021 — Revised guidelines for...
To get more flexibility and cost savings from storage, healthcare organizations are increasing their investments in the cloud
Feature | Information Technology | September 15, 2021 | By Kumar Goswami
Healthcare organizations today are storing petabytes of medical imaging data — lab slides,...
Figure 1: MWT Schematic of a typical setup for detecting malignant tissues/tumors.

Figure 1: MWT Schematic of a typical setup for detecting malignant tissues/tumors.

Feature | Radiology Imaging | September 14, 2021 | By Brendon McHugh
As with all imaging technologies, COVID-19 is expected to continue to negatively impact the market.

Courtesy of Grand View Research

Feature | Magnetic Resonance Imaging (MRI) | September 14, 2021 | By Melinda Taschetta-Millane
Plan to attend RSNA21 at McCormick Place Chicago, Nov. 28 – Dec. 2, 2021

Getty Images

News | RSNA | September 13, 2021
September 13, 2021 — The Radiological Society of North America (RSNA) today announced highlights of the Technical Exh
New recommendations will help provide more reliable, reproducible results for MRI-based measurements of cartilage degeneration in the knee, helping to slow down disease and prevent progression to irreversible osteoarthritis, according to a special report published in the journal Radiology

Knee cartilage compartments with anatomic labels implemented in lateral (left side), central (middle), and medial (right side) MRI obtained with an intermediate weighted fat-saturated fast-spin-echo sequence (top row) and a spin-lattice relaxation time constant in rotating frame (T1r) magnetization-prepared angle-modulated partitioned k-space spoiled gradient echo snapshots sequence (bottom row, T1r maps). Study was performed without administration of intravenous gadolinium-based contrast material. The lateral femur (LF)/medial femur (MF) and lateral tibia (LT)/medial tibia (MT) can be further divided into subcompartments on the basis of meniscus anatomy according to Eckstein et al. P = patella, T = trochlea.  Chalian et al, Radiology 2021 301; 7 ©RSNA 2021

News | Magnetic Resonance Imaging (MRI) | September 10, 2021
September 10, 2021 — New recommendations will help provide more reliable, reproducible results for...
Neuroscientists at the Beckman Institute for Advanced Science and Technology carried out comparative studies to determine safe operating conditions for multiband EEG-fMRI imaging while maintaining acceptable data quality standards

A team of psychologists and neuroscientists at the Beckman Institute for Advanced Science and Technology including Sepideh Sadaghiani, Maximillian Egan, Ryan Larsen, and Brad Sutton published a study to establish safe use of electroencephalography coupled with newly developed functional MRI sequences. Image courtesy of the Beckman Institute for Advanced Science and Technology.

News | Magnetic Resonance Imaging (MRI) | September 07, 2021
September 7, 2021 — A team of psychologists and neuroscientists at the Beckman Institute for Advanced Science and Tec